Latest News

 07/10/22

Endorsement (godkendelse)

  1. En samlet beskrivelse og opsummering af den videnskabelige baggrund af anvendelse af StressMeter målingen og den tilknyttede behandling som beskrevet af det uvildige forskerhold. Læs link

  2. DES kongres juni 2022 om hvordan Stressmeter måling kan bruges til en bedre forståelse af hjernens styring af blodsukkeret ved type 2 diabetes og den tilknyttede behandling kan hjælpe personerne til en forbedre regulering af deres blodsukker.

    1. Abstract Læs link

    2. Præsentation Læs link

  3. Lundbeck kongres november 2021 om anvendelse af teknologien til forstå koblingen mellem hjerne og depression hos hjertepatienter og hvordan teknologien kan hjælpe disse mennesker til et bedre liv og en forbedret overlevelse

    1. præsentation Læs link

  4. Nyt studie for personer med type 1 diabetes tanke på at bedre styringen af dagligdagens stress og dermed af hjernens styring af blodsukkeret

    1. Protokol resume over et videnskabeligt forsøg der i august 2022 er startet på Steno Diabetes Center Copenhagen Læs link

  5. Nyt i pressen

    1. Berlingske web avis august 2022 om hvordan StressMeter målingen og den tilknyttede behandling kan hjælpe almindelige raske og stressede mennesker til at forstå stress bedre og også håndtere det bedre Læs link

 23/07/21

The PPS measure is predictive for survival in heart disease patients and the Intervention improves survival

1)    Autonomic nervous system dysfunction (i.e. imbalance in the unconscious part of the nervous system) is known to be associated with multiple conditions, including stress, insomnia, allergies, type 2 diabetes, and heart disease. Treatment by pharmaceutical or surgical means addresses symptoms but has no known effect on the autonomic dysfunction. Although autonomic dysfunction is known to have a negative impact on survival for heart patients, there is no known measure of central autonomic dysfunction or evidence-based treatment which can reduce the autonomic dysfunction.

2)    Central autonomic dysfunction is reflected in elevated measures of pressure-pain sensitivity (PPS) at the sternum.

3)   An non-pharmacological intervention with focus on self-reflection on daily PPS measurements and peripheral sensory nerve stimulation of the sternum dermatome is known to reduce measures of PPS. This treatment modality is described here.

4)    The present study showed that this non-pharmacological treatment, when compared to a control treatment given to comparable heart disease patients, reduces the 5-year all-cause mortality by approximately 80 %. 

5)    The study also showed that when compared to the general Danish population, the 5-year all-cause mortality of the active treatment was approximately 75 % lower, while that of the control treatment group was not different from the general population.

6)    We conclude that the used intervention designed to reduce central autonomic dysfunction provides survival benefits to patients with heart disease. 

 

An independent Medical Technology Assessment report recommends the use of the PPS technology and the associated non-pharmacological treatment for type 2 diabetes patient with the Danish public health care system

(see link – in Danish)